Lineage Cell Therapeutics operates as a publicly traded corporate entity listed on major public stock exchanges, meaning it is owned collectively by a vast base of institutional investors, mutual funds, specialized asset management firms, and public retail shareholders. Rather than being controlled by a single parent organization, its ownership distribution reflects open market trading dynamics, with executive officers and directors holding insider equity stakes.